Major Depression Research Study
Researchers at Arch Clinical Trials are conducting a study on the investigational drug BHV7000 for treating Major Depressive Disorder (MDD) in individuals currently experiencing a major depressive episode.
Fast Facts
Have Major Depressive Disorder
18-75 Years Old
Compensation Provided
Conducted in St. Louis, MO
Study Background
This study is testing a new drug to help treat Major Depressive Disorder (MDD), a serious condition that affects mood, behavior, and daily life.
MDD is more than just feeling sad—it’s a condition that can cause persistent feelings of hopelessness, a loss of interest in everyday activities, and significant challenges in daily functioning. For many people, MDD interferes with their ability to work, maintain relationships, or enjoy life. Current treatments don’t work for everyone, and there is a need for new medications to help those who continue to struggle with depression.
In this study, researchers are testing a new investigational drug (BHV7000) to see if it can improve the symptoms of MDD, particularly during a major depressive episode. The goal is to determine whether this drug is both safe and effective in helping people feel better, regain interest in daily activities, and improve their overall quality of life. By studying this drug, researchers hope to provide a new option for people who have not had success with other treatments.
Study Background
This study is testing a new drug to help treat Major Depressive Disorder (MDD), a serious condition that affects mood, behavior, and daily life.
MDD is more than just feeling sad—it’s a condition that can cause persistent feelings of hopelessness, a loss of interest in everyday activities, and significant challenges in daily functioning. For many people, MDD interferes with their ability to work, maintain relationships, or enjoy life. Current treatments don’t work for everyone, and there is a need for new medications to help those who continue to struggle with depression.
In this study, researchers are testing a new investigational drug (BHV7000) to see if it can improve the symptoms of MDD, particularly during a major depressive episode. The goal is to determine whether this drug is both safe and effective in helping people feel better, regain interest in daily activities, and improve their overall quality of life. By studying this drug, researchers hope to provide a new option for people who have not had success with other treatments.
Additional Information
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18-75
- Have Major Depressive Disorder with a history of at least one previous Major Depressive Episode
- Current depressive episode began between 8 weeks and 2 years ago
Exclusion Criteria:
- Pregnant or breastfeeding
- On antidepressants (unless willing to discontinue)
If you participate in this study for Major Depressive Disorder (MDD), here’s an overview of what you can expect:
Screening: You’ll undergo an initial screening visit (about 4-6 hours) to determine if you’re eligible to participate in the study. This includes medical history review, mental health assessments, and possibly some physical exams.
Study Drug Treatment: This is a double-blind study, which means neither you nor the researchers will know whether you’re receiving the investigational drug or a placebo. This helps ensure unbiased results. You will be taking the study drug for the duration of the study.
Study Visits: Over the 12 weeks, you’ll have 7 onsite visits and 2 telephone calls. Each onsite visit will generally last around 2 hours, except the screening visit, which will be longer. These visits will involve assessments of your mental and physical health, possibly including blood tests, questionnaires, and evaluations of how well the study drug is working.
Safety and Monitoring: Researchers will regularly monitor your safety and how you’re responding to the treatment. This includes tracking any side effects, changes in your depression symptoms, and overall well-being.
Purpose: The goal is to test the safety and effectiveness of the study drug for treating MDD, including whether it helps improve your ability to enjoy daily activities and enhances your quality of life.
Duration: The study lasts about 12 weeks in total.
If you decide to participate, your involvement could help advance treatment options for Major Depressive Disorder while also providing you with regular health assessments and support throughout the process.
Yes, you will be compensated for your participation in the study. Here’s the breakdown of the payments:
- Screening: $200
- Observation/Telephone Call: $75.00
- Baseline: $150.00
- Week One: $150.00
- Week Two: $150.00
- Week Four: $150.00
- Week Six ET/EOT: $150.00
- Safety Follow-Up Week 2: $150.00
So, you’ll receive payments throughout different stages of the study. Lyft will be offered for all visits if you need assistance in transportation.
There is no cost for you to participate in our research study.